Novavax begins Phase II study for Covid-19-Influenza vaccines

Novavax has commenced a Phase II trial for its Covid-19-Influenza Combination (CIC) as well as influenza-only vaccine candidates.

The randomised, observer-blinded, dose-confirming trial has been designed for assessing the effectiveness (immunogenicity) and safety of various formulations of the CIC and influenza vaccine candidates in participants aged 50 to 80 years.